🇺🇸 FDA
Company

ATOSSA

ATOSSA THERAPEUTICS, INC.

ATOS pharma USA

Quick answer

ATOSSA is a pharma company (ATOS) headquartered in SEATTLE, WA, USA with 10 tracked pipeline programs.

Pipeline (10)

project

ForeCYTE Breast Aspirator

Breast Cancer, Preneoplastic Conditions, BRCA

Phase 3 · other · terminated

1 trials project

(Z)-endoxifen

Breast Neoplasms

Phase 2 · small_molecule · active

1 trials project

ASCAPE-based follow-up strategy

Breast Cancer

Phase 2 · other · active

1 trials project

Fulvestrant

Female Breast Carcinoma

Phase 2 · small_molecule · terminated

1 trials project

Provox Vega voice prosthesis 22.5 Fr

Total Laryngectomy

Phase 2 · other · completed

1 trials project

Provox voice prosthesis

Total Laryngectomy

Phase 2 · other · completed

1 trials project

Topical endoxifen

Mammographic Breast Density

Phase 2 · small_molecule · completed

1 trials project

Z-Endoxifen

Breast Density

Phase 2 · small_molecule · completed

1 trials project

AT-301B

Healthy

Phase 1 · small_molecule · completed

1 trials project

Provox Xtra HME

Total Laryngectomy

Phase 1 · other · completed

1 trials

Patents (8)

patent

US 12281056

Methods for making and using endoxifen

Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12275684

Methods for making and using endoxifen

Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12201591

Sustained release compositions of endoxifen

Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12071391

Methods for making and using endoxifen

Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11680036

Methods for making and using endoxifen

Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11572334

Methods for making and using endoxifen

Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11261151

Methods for making and using endoxifen

Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 6894026

Long-acting oxytocin analogues for the treatment and prevention of breast cancer

Expires Mon May 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)